Introduction {#s1}
============

Stroke prevention is central to atrial fibrillation (AF) treatment, and guidelines support use of oral anticoagulants (OAC) for AF patients at elevated risk for stroke ([@B1]). Three out of four AF patients aged 65 and older meet guideline criteria for OAC treatment ([@B2]).

Historically, use of an OAC for stroke prevention in AF meant use of a vitamin K antagonist (VKA). This treatment often requires frequent testing and dosing changes, since fluctuations in VKA response can result from diet, comorbid diseases, genetic variations, and drug-drug interactions. Four direct oral anticoagulants (DOACs) have been approved by the FDA for stroke prevention in non-valvular AF. These include: dabigatran, a direct thrombin inhibitor, and three factor Xa inhibitors, rivaroxaban ([@B3]), apixaban, and edoxaban ([@B4]). Recent AF management guidelines suggest that these agents be considered as first-line therapy for AF ([@B5]).

Despite the inclusion of older patients in several clinical trials comparing DOACs vs. VKA ([@B6]--[@B8]), many older patients were excluded due to comorbid illnesses. Since advanced age and common comorbidities may alter the pharmacokinetics of DOACs, the decision to prescribe a VKA or DOAC in "real-world" patients remains a conundrum. Although post-market surveillance studies show similar outcomes among DOAC and VKA-treated patients, few studies have examined differences in factors related to aging that strongly impact treatment outcomes ([@B9]). Conditions common in older patients, such as cognitive impairment, frailty, and social isolation adversely impact patient outcomes and are increasingly recognized as important components of prescribing decision making ([@B10]--[@B17]). In response to accumulating data that psychosocial factors influence treatment outcomes in older patients, AHA/ACC Guidelines for AF Management ([@B1]), as well as the AHA/ACC guidelines for other cardiovascular conditions, such as AMI, include consideration of CI, depression and social support in patient management ([@B18]). Also, geriatrics-specific guidelines for acute coronary care were developed by the AHA and ACC in 2007 ([@B19]), further highlighting the increasing attention to age-related factors in the management and outcomes of CVD. Although several of these conditions have been examined for their association with AC prescribing ([@B20]), whether type of AC prescribed varies according to psychosocial and geriatric conditions has not been examined.

Using data from the ongoing Systematic Assessment of Geriatric Elements in Atrial Fibrillation (SAGE-AF) prospective cohort study, we examined the characteristics of patients treated with DOACs vs. VKAs in a "real-world" cohort of older patients with AF. The objective of this study was to examine the prevalence of geriatric conditions among older patients with AF on OAC and relate type of OAC to geriatric conditions. We hypothesized that the presence of geriatric conditions would be associated with lower odds of receiving DOACs vs. VKAs. Further, we hypothesized that geriatric conditions would have different associations with prescribing patterns in younger vs. older patients with AF.

Materials and Methods {#s2}
=====================

SAGE-AF is an ongoing study of AF, OAC treatment, and relations between geriatric conditions and clinical outcomes in adults aged 65 years and older. Consenting participants completed a comprehensive baseline geriatric assessment, a structured interview, and review of their medical records.

To be eligible for SAGE-AF, participants must have: (1) been scheduled for an ambulatory care visit at a practice in Massachusetts or Georgia, (2) had a history of AF documentation on an electrocardiogram, Holter monitor, clinic note, or hospital record, and (3) had a CHA~2~DS~2~VASC risk score ≥2 (indication for OAC) ([@B2]). Participants were not eligible for enrollment if they had documentation of an OAC contraindication, had an indication for OAC other than AF, did not demonstrate capacity to provide informed consent ([@B21]), did not speak English, had a planned invasive procedure with possible uncontrollable bleeding, were pregnant, were in prison, or were unwilling or unable to participate in follow-up visits at their study sites.

All participants received an invitation to participate before their clinic visit. All participants provided written consent, and all study protocols were approved by the respective Institutional Review Boards. Between June 2016 and August 2018, 1,244 patients were enrolled.

All SAGE-AF participants had a medical history and physical examination performed in the context of their routine care. Trained study staff abstracted all demographic, clinical, treatment, and laboratory characteristics from participants\' medical records. All participants underwent a comprehensive interview that included a 6-component geriatric assessment using validated measures of frailty, cognitive function, social support, depressive symptoms, vision, and hearing. Frailty was assessed using the Cardiovascular Health Survey (CHS) frailty scale ([@B22]), a biological model of frailty based on five components: weight loss/shrinking; exhaustion; low physical activity (Minnesota Leisure Time Activity questionnaire) ([@B23]); slow gait speed (15-foot timed walk); and weakness (grip strength). Each element receives a single point and the frailty index ranges from 0 to 5. Based on the CHS scoring guidelines ([@B22]), a participant is frail if 3 or more criteria are present, pre-frail if 1 or 2 criteria are present, and not frail if 0 criteria are present.

To assess cognition, participants completed the Montreal Cognitive Assessment Battery (MoCA), a 30-item screening tool designed to assist care healthcare providers in detecting mild cognitive impairment. A cut-point of 23 was used to classify cognitive impairment ([@B24]). The 6-item Social Network Scale was used to assess the participants\' social networks and a cut-point of \<12 was used to define social isolation ([@B25]). This measure of social isolation reflects social connectedness; whether a person has friends or family members to talk to about important issues or to call when they need help. Social isolation is linked to higher rates of disability, poorer recovery from illness and death ([@B26]--[@B28]). The 9-item Patient Health Questionnaire (PHQ-9) was used to assess depressive symptoms with a score of five used as a cut-point for depressive symptoms ([@B29]). Patients self-report vision and hearing impairments ([@B30], [@B31]).

Statistical Analysis {#s3}
====================

We compared the characteristics of SAGE-AF participants who received OAC according to type of OAC (DOAC vs. VKA) using analysis of variance for continuous variables and *chi square* tests for categorical variables. We examined which geriatric elements (independent variables: cognitive function, frailty, social isolation, vision impairment, hearing impairment, depression) were associated with OAC treatment type using adjusted logistic regression analysis. In these analyses, we adjusted for each geriatric element and then additionally for clinical and demographic factors identified from univariate analyses as being associated with treatment type at the *p* \< 0.15 level. Differences in the clinical and treatment characteristics were noted between participants from Massachusetts and Georgia. As such, we conducted stratified regression analyses by study site and adjusted for factors associated with OAC type. We also stratified our regression analyses by age (65--74 years vs. ≥75 years) since we were interested in whether geriatric conditions influenced OAC prescription choice differently among older and younger participants.

Results {#s4}
=======

86% of the 1244 SAGE-AF participants were prescribed an OAC. Of the participants prescribed an OAC, we excluded 15 participants missing data on one or more of the variables included in the analysis, resulting in an analytic sample of 1,064 older patients with AF prescribed an OAC.

Of these participants, 44% were prescribed a DOAC and 56% were prescribed VKA. Among those prescribed a DOAC, the majority received apixaban (*n* = 238) and rivaroxaban (*n* = 184), with a minority of participants receiving dabigatran (*n* = 40) or edoxaban (*n* = 4). There was a high burden of cardiovascular and non-cardiovascular comorbidities, including prior bleeding and geriatric conditions ([Table 1](#T1){ref-type="table"}). Women comprised about half of the study sample, 85% were white, two-thirds were frail or pre-frail, and 22% had suffered a fall in the last 6 months. Differences in the overall proportion of DOAC treated participants and factors associated with type of OAC prescribed were noted in Massachusetts vs. Georgia ([Supplemental Table 1](#SM1){ref-type="supplementary-material"}).

###### 

Characteristics of older adults with atrial fibrillation on oral anticoagulation, according to type of oral anticoagulation: SAGE-AF, 2016--2018.

  --------------------------------------------------------------------------------------------------------------------------------------------------
  **Characteristic**                                                              **Direct oral anticoagulant**\   **VKA**\          ***p*-value**
                                                                                  **(*n* = 466)**                  **(*n* = 598)**   
  ------------------------------------------------------------------------------- -------------------------------- ----------------- ---------------
  **DEMOGRAPHIC CHARACTERISTICS**                                                                                                    

  **Age**                                                                                                                            

  65--74 years                                                                    251 (53.9)                       268 (44.8)        \<0.001

  75--84 years                                                                    178 (38.2)                       223 (37.3)        

  85 years and older                                                              37 (7.9)                         107 (17.9)        

  Female                                                                          228 (48.9)                       297 (49.7)        0.81

  **Race/Ethnicity**                                                                                                                 

  White                                                                           380 (81.6)                       522 (87.3)        \<0.01

  Non-White                                                                       86 (18.5)                        76 (12.7)         

  **Marital status[^a^](#TN1){ref-type="table-fn"}**                                                                                 

  Married or living as married                                                    266 (57.1)                       327 (54.7)        0.73

  Not Married                                                                     193 (41.4)                       261 (43.7)        

  **Education[^b^](#TN2){ref-type="table-fn"}**                                                                                      

  High school/GED or less                                                         45 (9.7)                         45 (7.5)          0.22

  Some college                                                                    209 (44.9)                       310 (51.8)        

  College graduate                                                                75 (16.1)                        83 (13.9)         

  Graduate degree                                                                 130 (27.9)                       150 (25.1)        

  **Household income[^c^](#TN3){ref-type="table-fn"}**                                                                               

  \>= 50,000                                                                      208 (52.0)                       224 (46.0)        0.08

  **Insurance status[^d^](#TN4){ref-type="table-fn"}**                                                                               

  Commercial/HMO/PPO                                                              56 (12.0)                        128 (21.4)        \<0.01

  Medicare                                                                        350 (75.1)                       422 (70.6)        

  Other                                                                           59 (12.7)                        46 (7.7)          

  **CLINICAL CHARACTERISTICS**                                                                                                       

  **AF type**                                                                                                                        

  Paroxysmal                                                                      298 (64.0)                       302 (50.5)        \<0.001

  Persistent                                                                      118 (25.3)                       179 (29.9)        

  Permanent                                                                       19 (4.1)                         50 (8.4)          

  Unknown                                                                         31 (6.7)                         67 (11.2)         

  CHA~2~DS~2~VASC score (M, *SD*)                                                 4.3 (1.6)                        4.7 (1.6)         \<0.01

  HAS-BLED score (M, *SD*)                                                        2.8 (1.0)                        3.0 (1.0)         \<0.05

  AFEQT score (M, *SD*)                                                           78.2 (18.9)                      80.5 (16.9)       \<0.05

  Bothered[^e^](#TN5){ref-type="table-fn"} by ≥1 AF symptom in the past 4 weeks   61 (13.2)                        55 (9.2)          \<0.05

  **Medical history**                                                                                                                

  Acute myocardial infarction                                                     89 (19.1)                        123 (20.6)        0.55

  Alcohol abuse/dependency                                                        165 (35.4)                       168 (28.1)        \<0.05

  Anemia                                                                          122 (26.2)                       212 (35.5)        \<0.01

  Bleeding                                                                        97 (20.8)                        112 (18.7)        0.4

  Chronic kidney disease                                                          115 (24.7)                       195 (32.6)        \<0.01

  Chronic lung disease                                                            123 (26.4)                       145 (24.3)        0.42

  Diabetes                                                                        140 (30.0)                       166 (27.8)        0.41

  Heart failure                                                                   159 (34.1)                       250 (41.8)        \<0.05

  Hyperlipidemia                                                                  354 (76.0)                       495 (82.8)        \<0.01

  Hypertension                                                                    415 (89.1)                       551 (92.1)        0.08

  Implantable cardiac device                                                      163 (35.0)                       203 (34.0)        0.73

  Peripheral vascular disease                                                     57 (12.2)                        93 (15.6)         0.12

  Stroke                                                                          40 (8.6)                         68 (11.4)         0.13

  Creatinine (mg/dL) M (*SD*)                                                     1.05 (0.37)                      1.15 (0.65)       \<0.05

  Hemoglobin (g/dL) M (*SD*)                                                      13.1 (1.9)                       13.1 (1.8)        0.96

  **TREATMENT CHARACTERISTICS**                                                                                                      

  Aspirin                                                                         104 (22.3)                       204 (34.1)        \<0.001

  Clopidogrel                                                                     30 (6.4)                         25 (4.2)          0.07

  **OVERALL TREATMENT SATISFACTION**                                                                                                 

  Extremely satisfied                                                             203 (43.8)                       286 (48.0)        0.41

  Very satisfied                                                                  147 (31.7)                       187 (31.4)        

  Somewhat satisfied                                                              61 (13.2)                        64 (10.7)         

  Satisfied or less than satisfied                                                53 (11.4)                        59 (9.9)          

  **PSYCHOSOCIAL CHARACTERISTICS**                                                                                                   

  Fall in past 6 months                                                           91 (19.5)                        143 (23.9)        0.09

  Anxiety[^f^](#TN6){ref-type="table-fn"}                                         115 (24.7)                       137 (22.9)        0.50

  Living Alone                                                                    128 (27.5)                       167 (27.9)        0.87

  Independence (IADLs)                                                            6.8 (0.9)                        6.6 (1.1)         \<0.05

  Confident in physician interactions[^g^](#TN7){ref-type="table-fn"}             302 (66.8)                       374 (64.3)        0.39

  **Practice type**                                                                                                                  

  Cardiologist                                                                    139 (29.8)                       349 (58.4)        \<0.001

  EP                                                                              319 (68.5)                       233 (39.0)        

  Internist                                                                       8 (1.7)                          16 (2.7)          
  --------------------------------------------------------------------------------------------------------------------------------------------------

*n = 17 missing Marital Status*.

*n = 17 missing Education*.

*n = 177 missing household income*.

*n = 3 missing Insurance Status*.

*quite/extremely/very bothered with symptoms*.

*anxiety GAD7 \<= 5*.

*defined based on a PEPPI score of \>45*.

Geriatric conditions, including frailty, depression, cognitive impairment, social isolation, and visual and hearing impairments were common ([Table 1](#T1){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}). Given the high rate of cardiovascular comorbidity, study participants were at high risk for thromboembolic, and bleeding complications based on their CHA~2~DS~2~VASC and HAS-BLED risk scores. Slightly more than three quarters (78%) of study participants reported being satisfied or very satisfied with their overall treatment.

![Number of older adults with atrial fibrillation on oral anticoagulation, according to type of oral anticoagulation, and frailty category: SAGE-AF, 2016-2018. Not frail, 0 impairments; Pre-frail, 1--2 impairments; Frail, 3--5 impairments (impairments include unintentional weight loss, weakness, exhaustion, slow gait, low physical activity) as defined by the CHS Frailty Scale ([@B22]).](fcvm-06-00155-g0001){#F1}

In comparison to participants receiving VKA, participants treated with DOACs were, on average, younger, and had lower average stroke and bleeding risk scores ([Table 1](#T1){ref-type="table"}). Notably, participants treated with DOACs were more likely to have paroxysmal AF, have had a symptomatic episode in the last 4 weeks, have seen a cardiologist or cardiac electrophysiologist, and have reported lower OAC burden and higher disease-specific quality of life ([@B32]). Finally, participants receiving DOACs were less likely to be frail or pre-frail and had greater independence in activities of daily living but were more likely to report social isolation.

Among participants enrolled in Massachusetts, frail, pre-frail, and cognitively impaired status were associated with 40, 46, and 35% lower odds, respectively, of being treated with DOAC ([Table 2](#T2){ref-type="table"}). After adjustment for stroke and bleeding risk scores as well as other factors associated with type of OAC, pre-frail status was associated with a significantly reduced odds of being prescribed a DOAC (*OR* = 0.64, 95% CI 0.45, 0.91; [Table 2](#T2){ref-type="table"}). When we stratified our analyses by age, pre-frail status, and social isolation were associated with a more than 60% lower odds of DOAC-receipt in older (\>75 years) participants enrolled in Massachusetts ([Table 3](#T3){ref-type="table"}). In contrast, low social isolation was associated with an approximately 2-fold higher rate of DOAC receipt among younger (65--74 years) participants enrolled in Massachusetts ([Table 3](#T3){ref-type="table"}). The sample size in Georgia was not large enough to examine these associations among patients in Georgia.

###### 

Receipt of DOAC vs. VKA by geriatric element status among older adults with atrial fibrillation treated with oral anticoagulation enrolled in Massachusetts (*n* = 818): SAGE-AF, 2016--2018.

  -----------------------------------------------------------------------------------------------------------------
                                               **Odds of receiving a DOAC**                                
  ---------------------- ------------ -------- ------------------------------ -------- ------------------- --------
  Frailty                                                                                                  

     Frail               29 (10.4)    \<0.01   0.60 (0.37, 0.99)              0.41     0.88 (0.48, 1.61)   0.74\
                                                                                                           \<0.05

     Pre-frail           126 (45.3)            0.54 (0.39, 0.74)              \<0.05   0.64 (0.45, 0.91)   

     Not frail           123 (44.2)            (Reference)                             (Reference)         

  Cognitive impairment   89 (32.0)    \<0.05   0.65 (0.48, 0.89)              \<0.01   0.95 (0.67, 1.34)   0.76

  Social isolation       28 (10.1)    0.97     1.01 (0.62, 1.63)              0.97     1.11 (0.66, 1.86)   0.70

  Visual impairment      82 (29.5)    0.46     0.89 (0.65, 1.22)              0.46     1.02 (0.72, 1.44)   0.91

  Hearing impairment     103 (37.1)   0.57     0.92 (0.68, 1.24)              0.57     1.03 (0.75, 1.43)   0.85

  Depression             65 (23.4)    0.17     0.79 (0.57, 1.11)              0.17     0.79 (0.53, 1.19)   0.27
  -----------------------------------------------------------------------------------------------------------------

*M1, Unadjusted logistic regression model for each geriatric element (main independent variables): frailty, cognitive impairment, social isolation, sensory impairments (visual and hearing), depression; M2, M1 additionally adjusted for risk scores (CHA~2~DS~2~VASC, HAS-BLED), education, insurance, AF type, AFEQT score, hyperlipidemia, alcohol abuse, anemia, CKD, aspirin use, fall in past 6 months, IADL, provider type, frailty, and cognitive impairment. Age was accounted for via CHA~2~DS~2~VASC*.

###### 

Receipt of DOAC vs. VKA by geriatric element status among older adults with atrial fibrillation treated with oral anticoagulant enrolled in Massachusetts, further stratified by age (75-years cutoff): SAGE-AF, 2016--2018.

  **Geriatric elements**          **DOAC *N* (%)**   ***p*-value**   **M1 unadjusted OR (95% CI)**   ***p*-value**   **M2 adjusted OR (95% CI)**   ***p*-value**
  ------------------------------- ------------------ --------------- ------------------------------- --------------- ----------------------------- ---------------
  **\<75 (*****N*** **= 406)**                                                                                                                     
  Frailty                                                                                                                                          
     Frail                        12 (7.4)                           0.60 (0.28, 1.26)               0.27            0.84 (0.35, 2.01)             0.73
     Pre-Frail                    72 (44.4)          0.30            0.80 (0.53, 1.21)               0.90            0.94 (0.59, 1.50)             0.93
     Not frail                    78 (48.2)                          (Reference)                                     (Reference)                   
  Cognitive impairment            45 (27.8)          0.84            0.96 (0.62, 1.49)               0.84            1.39 (0.84, 2.31)             0.20
  Social isolation                22 (13.6)          0.11            1.67 (0.89, 3.15)               0.11            2.13 (1.05, 4.29)             \<0.05
  Impaired vision                 52 (32.1)          0.75            0.93 (0.61, 1.43)               0.75            1.20 (0.75, 1.93)             0.45
  Impaired hearing                51 (31.5)          0.22            1.32 (0.85, 2.05)               0.21            1.44 (0.89, 2.34)             0.14
  Depression                      37 (22.8)          0.11            0.69 (0.44, 1.10)               0.12            0.71 (0.40, 1.26)             0.24
  **\>=75 (*****N*** **= 412)**                                                                                                                    
  Frailty                                                                                                                                          
     Frail                        17 (14.7)          \<0.01          0.63 (0.32, 1.25)               0.99            0.56 (0.23, 1.41)             0.97
     Pre-frail                    54 (46.6)                          0.39 (0.24, 0.63)               \<0.01          0.33 (0.18, 0.59)             \<0.01
     Not frail                    45 (38.8)                          (Reference)                                     (Reference)                   
  Cognitive Impairment            44 (37.9)          \<0.01          0.55 (0.35, 0.85)               \<0.01          0.67 (0.40, 1.11)             0.12
  Social isolation                6 (5.2)            \<0.05          0.44 (0.18, 1.07)               0.07            0.38 (0.14, 0.99)             \<0.05
  Impaired vision                 30 (25.9)          0.32            0.79 (0.49, 1.27)               0.33            0.85 (0.49, 1.48)             0.56
  Impaired hearing                52 (44.8)          0.34            0.81 (0.53, 1.25)               0.35            0.84 (0.52, 1.35)             0.47
  Depression                      28 (24.1)          0.69            0.91 (0.55, 1.49)               0.69            0.94 (0.51, 1.75)             0.85

*M1, Unadjusted logistic regression model for each geriatric element individually (main independent variables): frailty, cognitive impairment, social isolation, sensory impairments (visual and hearing), depression; M2, M1 additionally adjusted for risk scores (CHA~2~DS~2~VASC, HAS-BLED), education, insurance, atrial fibrillation type, AFEQT score, hyperlipidemia, alcohol abuse, anemia, chronic kidney disease, aspirin use, fall in past 6 months, IADL, provider type, frailty, and cognitive impairment*.

Discussion {#s5}
==========

Over 80% of SAGE-AF participants were prescribed an OAC, a rate higher than has been reported in older cohorts but consistent with more recent data ([@B33]). This higher rate may also be explained by differences in the eligibility criteria used by our study, which required that participants not have active bleeding or other contraindications to OAC.

Although an increasing number of patients with AF are prescribed DOACs, VKAs are frequently used for stroke prevention ([@B34]). VKAs place a high burden on older patients, with dietary and lifestyle restrictions, frequent lab monitoring, and frequent dosage adjustments. We observed that 44% of anticoagulated study participants were treated with DOACs, a rate lower than has been reported in Europe and some specialized US centers ([@B33]), but slightly higher than what was reported by the IMS Health National Disease and Therapeutic Index (38%) ([@B35]). Consistent with national prescription rates, we observed that apixaban and rivaroxaban were the most commonly prescribed DOACs. Study region and prescriber type (cardiac electrophysiologist vs. other) were associated with type of OAC used for AF ([Table 1](#T1){ref-type="table"}).

Clinical trials and meta-analyses have suggested that DOACs may be safer than VKA in older trial participants ([@B36], [@B37]); however, many older patients were excluded from these studies based on commonly occurring comorbidities. The decision of VKA vs. DOACs in "real-world" patients remains a conundrum, since advanced age, and common comorbidities (e.g., renal impairment) increase the risk of adverse events from both agents ([@B38]). Moreover, in contrast to VKA, reversal agents for DOACs were not widely available during the study period, an important consideration for many providers since older patients with AF are at high risk for falls and traumatic bleeding ([@B39]).

Prior studies have shown that geriatric conditions, including cognitive impairment, frailty, and depression, are associated with a higher odds of not being prescribed OAC despite being eligible ([@B40], [@B41]); however, few studies have examined relations between geriatric conditions and type of OAC selected ([@B42], [@B43]). We hypothesized that older, frailer participants affected by a greater burden of geriatric conditions would be prescribed VKA, since these conditions are associated with renal impairment, polypharmacy, and other age-related factors that affect DOAC treatment.

Our finding that pre-frailty status (1--2 impairments) was associated with lower odds of being treated with a DOAC supports this hypothesis. Although the association between frailty status (more than 2 impairments) and greater odds of DOAC did not achieve statistical significance, the direction of the association was the same as pre-frailty ([Table 2](#T2){ref-type="table"}). We suspect the lack of statistical significance may have related to the smaller number of participants in the frail (vs. pre-frail) category. Furthermore, we observed a similar but statistically more robust finding among participants aged 75 years and older, but not among younger participants (65--74 years old). This suggests that the impact of geriatric conditions on OAC prescribing may be greatest among individuals older than 75 years of age. Furthermore, social isolation was associated with a 2-fold higher rate of DOAC use among younger patients. This relationship may be explained by the benefits of social support for handling the burden of monitoring and clinical follow-up required to manage VKA. However, among the oldest participants in our cohort, social isolation was associated with 62% lower odds of DOAC receipt. This counter-intuitive finding may be explained by AF patients or their providers perceiving frequent OAC clinic nurse evaluations and/or laboratory monitoring as a potential benefit for socially isolated elders.

Our findings have important potential clinical implications. Since AF patients in the pre-frail category were more likely to receive VKA, previously published secondary data analyses suggesting that DOACs have a favorable safety profile may suffer from unmeasured confounding ([@B43]). Second, patients receiving OAC had high rates of geriatric conditions, placing these individuals at elevated risk for OAC complications. In contrast to patients on VKA, patients receiving DOACs for AF are infrequently followed by anticoagulation clinics, nor do they systematically receive OAC education. Anticoagulation clinics support providers by helping to manage AF patients and perform routine drug safety and laboratory monitoring; however, these critical care pathways are not routinely made available to DOAC-treated patients.

Our findings also suggest that social isolation may influence OAC prescribing patterns and that the role of social isolation may differ among younger and older patients. Future studies should explore whether or how physicians and patients include the patient\'s social circumstances into conversations about treatment decision-making. Efforts to integrate support of DOAC-treated patients into traditional OAC clinics appear well-founded. Studies are needed to demonstrate that such supportive care improves patient outcomes.

The strengths of our study include the geographic diversity of the study cohort, inclusion of older AF patients with a high degree of comorbidity, and high rates of OAC use. Furthermore, the comprehensive assessment of factors associated with aging used validated and publicly available instruments that can be utilized in an office visit. Study limitations include the cross-sectional nature of our analysis. Information was not available about each participant\'s history or duration of exposure to OAC, and participants may have recently switched from DOAC to VKA or VKA to DOAC prior to study enrollment. However, prior studies show low overall rates of switching after initial OAC prescription, particularly among DOAC-treated patients ([@B42], [@B44]). Importantly, we had limited power to evaluate the associations between geriatric elements and use of DOACs among participants in Georgia, and thus cannot conclude whether the observed point estimates for these associations are statistically significant. Further research in other large, diverse samples are needed to validate our findings, especially considering the regional variation in OAC prescribing observed in our study.

Conclusions {#s6}
===========

In a well-characterized, diverse sample of older patients with AF treated with OAC, we observed that the rates of readily assessed geriatric conditions were high and that several geriatric conditions, including pre-frailty and social isolation, were associated with a lower likelihood of receiving a DOAC. In light of guideline changes favoring DOACs over VKA for safety and effectiveness ([@B5]), additional efforts to provide tailored OAC education and support to frail and socially isolated patients may be necessary.
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